Demegen,
Inc., based in Pittsburgh, Pennsylvania, is a biotechnology research company that
designs and develops novel synthetic compounds. The Company's primary focus is the
treatment of human and plant diseases, along with nutrition enhancement of food and feed
crops. The company's lead pharmaceutical compound has demonstrated the ability to
substantially reduce both solid and metastasized prostrate cancer tumors in mice and rats
without toxicity. The Company is planning to begin human clinical trials in 1999. |
